rnpowell

Author Archives

Sarepta and dystrophin

The FDA has asked Sarepta to reveal results of muscle biopsies to see how much new dystrophin was made after treatment with eteplirsen, but haven’t they already said studies only showed 0.9% increase? Will this new release provide any new information and give hope to Sarepta investors, not to mention patients and families, or is […]

Recent Author Comments

On "Top Stock Under $3?" What's Carr's teased "America's #1 Pot Stock?"
On a different subject, do you know anything about The Near Future Report written by Jeff Brown $49 per year? He claims to know a semiconductor manufacturer that makes a chip that will be in every 5 G phone which he will name for you if you sign up and [...]
On Ask a Stupid Question...
I am looking to purchase long term call options on CRSP and EDIT. I can only get EDIT options out to Jan 2020 and CRSP out to Oct 2018. How come I cannot get options further out on these stocks?[...]
On Looking Out for Your Own Wellbeing
Dear Michael, Regarding the question of whether you should get primary care from a primary care MD or a specialist who some think must be smarter of course since they are specialists. Consider the case of US Senator John East from Greenville NC. The se[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

Connect with Travis

website designed by Gravity Switch